We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sesen Bio Withdraws EU Application for Cancer Drug FDA Just Turned Down
Sesen Bio Withdraws EU Application for Cancer Drug FDA Just Turned Down
Sesen Bio has withdrawn its EU marketing authorization application for Vysyneum (oportuzumab monatox-qqrs) — called Vicineum in the U.S. — a week after FDA regulators denied approval for the bladder cancer drug.